Because now it is a game of wait-and-see. In the pre-Matria days IMA/ALR was gobbling up new diagnostics companies and distribution companies left and right so there was always something to talk about or debate. Now that they've vertically integrated across their entire supply chain from source material to distribution, and horizontally expanded via diagnostic acquisitions, they've moved onto their next phase of development: creating a market in home care.
With their molecular platform, they aim to be the first mover in a brand new healthcare configuration where people are tested in their home and monitored by their doctors remotely. So far it appears to be working, but the big picture is going to take a while to unfold, and it is still yet to be determined whether this model will move beyond chronic disease care and into everyday health monitoring of the general public.
I've lost a lot of money on IMA/ALR, yet I'm still fascinated by the company, and still continue to invest (though at a very reduced amount these days).